The trend of reducing health care costs through global capitation and aggressive contracting from payer/provider integration has and will continue to expand in the health care market. This combination will provide a solid singular force in reducing cost and improving outcomes. Recent announcements of unusual entities entering the market, such as Amazon, CVS, and Walmart, are an example of this phenomenon.
One of the key topics in health care relates to how to change patient behavior. Over the years, many programs have been developed and implemented with varying results. In 2011, Professor Susan Mitchie and colleagues at the University College of London conducted an intensive search and spoke with several behavioral change experts to identify 19 programs that addressed health-related behavior change. After conducting an in-depth analysis, the researchers observed that none of the programs used an underlying theoretical approach or covered key areas of behavior change.
New policies and legislation related to health care reform mean that control over prescription drugs selections may also shift within different markets. For providers and provider groups creating clinical protocols for a disease state, it is important to understand the various stakeholder biases in real-world contexts, so that appropriate prompts may be integrated into the protocol in order to achieve the best outcomes.
Yesterday CVS made an offer to acquire Aetna. This is a true game changer for 2 reasons. The first is that it represents the most significant national integration of a service provider and a payer.
Often when older adults find themselves with an acute medical problem, they dial 9-1-1, ending up in an emergency room with a likely admission. This path is costly, both from a clinical and a financial standpoint.
The World Congress 1st Annual ACO and IDN Collaboration for Population Health Delivery Summit is taking place on October 23-24, 2017, in Alexandria, Virginia. It will highlight new models for advancing accountable care organization (ACO), integrated delivery network (IDN), and life science partnerships in population health management. Through hands-on learning and high-level strategy sessions, life science executives will become equipped with the tools needed to become a trusted health care partner and prove value beyond the brand.
Clinical pathways should address all three aspects of the Triple Aim, but the aim of improving population health is often prioritized at the expense of improving the patient experience of care and reducing the cost of health care. The latter two aspects could be better achieved by providing care that is consistent with an individual patient’s health objectives.
Even though physicians make correct diagnoses and prescribe the right treatments, that does not mean patients will fill their prescriptions and take every pill. There are several points along the patient journey at which people get sidetracked and stop taking their medications.
July 26, 2017
For 5 straight years, The Access Group has been recognized as one of the Top 100 Agencies by MM&M thanks to the company’s leading-edge work in managed markets.
Based on his speech to a joint session of Congress a few months ago, President Trump’s love/hate relationship with pharma will undoubtedly affect the care of many patients.
As health systems expand both in size and number, a corresponding trend has emerged for these organizations to increase their level of risk and clinical integration, with an emphasis on efficient and effective population health management.
There is one story as to why the American Health Care Act (AHCA) did not get through Congress but while there is only one story there are two very different meanings. The story goes that the AHCA would have resulted in 24M Americans losing health insurance while producing very little savings – about $700 per person per year. One translation – Americans would be better off with ObamaCare and therefore there was not enough support for the bill.
In the wake of the passing of the 21st Century Cures Act last December, Food and Drug Administration (FDA) released several guidance documents aimed at providing manufacturers with expanded regulatory latitude for product-related communications and promotion. With mounting pressure from industry and advocacy to expedite market approval of new therapies, FDA’s efforts signals a leaning to release or minimize regulatory restrictions that in the past have restricted the ability of manufacturers to promote products.
After attempting to repeal the Affordable Care Act more than 60 times in the last 5 years, Republican lawmakers have a chance to dismantle the health care law as early as the next few weeks. Last month, the House and Senate passed a bill that could be used to cut funds to key parts of the legislation. However, Republicans remain divided over how fast to move on repealing Obamacare without having a viable replacement plan ready to implement.